Specialty Pharma Journal Specialty, Precision & Technology
Mechelen, Belgium, 29 November 2018 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces it has entered into an agreement with AstraZeneca, a global science-led biopharmaceutical company (LON: AZN), aimed at obtaining faster lung cancer molecular diagnostic biomarker results in Europe. …
Tag Archives: diagnostics
November, 2018
September, 2018
-
27 September
Agilent to Expand Portfolio and Capabilities in Cell Analysis with Acquisition of ACEA Biosciences
SANTA CLARA, Calif.–(BUSINESS WIRE)–Agilent Technologies Inc. (NYSE: A) today announced it has signed a definitive agreement to acquire privately-owned ACEA Biosciences Inc. (ACEA), a developer of cutting-edge cell analysis instruments for life science research and clinical diagnostics, for $250 million in cash. “Expanding our cell analysis footprint is a key strategic …
August, 2018
-
2 August
Castle Biosciences’ DecisionDx-Melanoma Test Improved AJCC-Based Risk Prediction for Melanoma Recurrence and Metastasis
FRIENDSWOOD, Texas–(BUSINESS WIRE)–Castle Biosciences, Inc., the skin cancer diagnostics company providing molecular diagnostics to improve cancer treatment decisions, today announced the presentation of new data showing that the DecisionDx®-Melanoma test improved risk prediction beyond that using American Joint Committee on Cancer (AJCC) based staging. The study was presented at the …
June, 2018
-
7 June
Centogene Partners with the Universities of Greifswald and Rostock to Develop Fast-Tracked Diagnostic Workflow for Personalized Therapies for Colon and Pancreatic Tumors
ROSTOCK, Germany–(BUSINESS WIRE)–CENTOGENE, the worldwide leader in using genetic and proteomic knowledge to enable patients, clinicians and pharmaceutical partners to identify and accelerate treatments for rare diseases, today announced partnering with the Medical Faculties of the Universities of Greifswald and Rostock for the research project, “Development of diagnostic tools for …
May, 2018
-
24 May
Quest Diagnostics Study Finds Physicians Lack the Time and Tools to Discover Hidden Risks in Patients with Chronic Conditions
SECAUCUS, N.J., May 23, 2018 /PRNewswire/ — The vast majority of primary care physicians don’t have the time or tools to adequately address the needs of their patients with multiple chronic conditions, leaving some patients to struggle with health-related social and behavioral issues on their own, according to new research …
July, 2017
-
31 July
LabCorp to Acquire Specialty CRO Chiltern for $1.2 Billion in Cash
BURLINGTON, N.C. & WILMINGTON, N.C. & LONDON–(BUSINESS WIRE)–LabCorp® (NYSE:LH), a leading global life sciences company, and Chiltern, a specialty CRO, announced today that LabCorp will acquire Chiltern pursuant to a definitive agreement with Chiltern’s shareholders in an all-cash transaction valued at approximately $1.2 billion. Once the transaction is complete, Chiltern …
May, 2017
-
16 May
Alexion and Rady Children’s Institute for Genomic Medicine Partner to Speed Diagnosis of Rare Genetic Disorders in Newborns
SAN DIEGO & NEW HAVEN, Conn.–(BUSINESS WIRE)–The Rady Children’s Institute for Genomic Medicine (RCIGM) and Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced a strategic partnership to accelerate the diagnosis of critically-ill newborns with rare genetic disorders. The collaboration combines the Institute’s genomic research expertise with Alexion data science and bioinformatics capabilities …
April, 2017
-
14 April
Abbott Expands Diagnostics Business with $5.3 Billion Acquisition of Alere
ABBOTT PARK, Ill. and WALTHAM, Mass., April 14, 2017 /PRNewswire/ — Abbott (NYSE: ABT) and Alere Inc. (NYSE: ALR) announced today that the companies have agreed to amend the existing terms of their agreement for Abbott’s acquisition of Alere. Under the amended terms, Abbott will pay $51 per common share to …
February, 2017
-
8 February
Cannabics Announces Commercialization of Cannabinoids-Based Personalized Diagnostics for Cancer Patients
BETHESDA, Maryland, Feb. 6, 2017 /PRNewswire/ — Cannabics Pharmaceuticals Inc. (CNBX) today announced it will begin providing personalized cannabinoid anti-tumor tests for cancer patients. The diagnostic tests are based on liquid biopsies of patients suffering from any kind of cancer. The test uses CTC technology that collects cancer cells from patients’ …
July, 2016
-
8 July
FDA Approves First HPV Test for Use with SurePath Preservative Fluid
The U.S. Food and Drug Administration today approved the Roche cobas HPV Test as the first test for Human Papilloma Virus (HPV) that can be used with cervical cells obtained for a Pap test and collected in SurePath Preservative Fluid. The FDA approves HPV tests to be used with specific …